Mark Levick is the CEO of Alvotech. Before joining the Company, he worked as the global head of development of Sandoz Biopharmaceuticals (a business unit of Novartis) since 2016. During this time, Mark oversaw the successful approval of biosimilar medicines in major markets, taking Sandoz to the industry-leading position with a total of eight approved biosimilar products. Previously Mark also held roles of increasing responsibility at Novartis in the USA and Switzerland, including the head of biologics, clinical development and respiratory development, and played a pivotal role in the approval of innovative biopharmaceutical medicines. Prior to Novartis, Mark held leadership roles in biopharmaceutical development at GlaxoSmithKline in the UK and USA and served as a medical reviewer at the UK’s Medicines and Healthcare Products Regulatory Agency and European Medicines Agency.

Before joining the industry, Mark held positions as a specialist clinician in teaching hospitals in the UK and Australia. He was awarded his medical degree from the University of Newcastle, Australia, and studied at the University of Cambridge in the UK as a Commonwealth scholar. He holds a PhD in vaccine development from Cambridge University, and is a fellow of the Royal College of Pathologists of Australasia and the Australasian College of Tropical Medicine.

Mark Levick

Tanya Zharov joined Alvotech as deputy chief executive officer in May 2020. Her principal responsibilities are focused on Icelandic operations and administration, including the Reykjavik site leadership team, human resources, business operations, shared services and facilities, in partnership with the CEO and members of the corporate leadership team.  

Tanya joined Alvotech, with a strong track record in innovation-driven global life sciences and business. Prior to joining Alvotech, she was the deputy CEO and compliance officer at deCODE genetics, a renowned world leader in human genetics, where she led the administrative team and assisted the CEO with many aspects of company operations, overseeing human resources and serving as compliance officer.

A lawyer by training, Tanya was also a founding partner and deputy CEO of Audur Capital, an Icelandic securities firm, where her responsibilities spanned legal affairs, wealth management, corporate finance, private equity and capital markets. Prior to that, as corporate counsel at deCODE genetics, Tanya led the securities regulation and compliance team behind the first US IPO by an Icelandic company. Tanya is a specialist in US and global public markets law, regulation and best practice. Early in her career, Tanya served as a tax partner at PricewaterhouseCoopers.

Tanya Zharov

Joe McClellan is Alvotech’s CSO.  In this capacity, he leads the company’s R&D functions, with overall responsibility for bringing products to market through its pipeline and overseeing R&D operations across Alvotech’s sites in Reykjavik, Julich, Hanover and Zurich.

Joe joins Alvotech with an outstanding track record in drug development with broad experience in all areas of biopharmaceutical development, including biosimilars, innovator biologics, pharmaceutical science, clinical development, regulatory strategy and discovery research.

Prior to joining Alvotech, Joe worked with Pfizer for 17 years in various capacities, including Global Head of Biosimilars Development and Medicine/Asset Team Leader of IXIFI (biosimilar infliximab). During Joe’s tenure leading Biosimilars Development at Pfizer, the company secured major market approvals for 6 unique biosimilar molecules.

Joe earned a Ph.D. degree in Chemistry, with a focus in Analytical Chemistry and Mass Spectrometry, from the University of Florida (Gainesville, FL USA). In addition, he was a Postdoctoral Fellow in Mass Spectrometry and Analytical Biochemistry at the Boston University School of Medicine (Boston, MA USA) and received a Master of Business Administration degree, with a focus on innovation and business growth in high-technology industries, from Northeastern University (Boston, MA USA).

Joseph E. McClellan

Sean joined Alvotech as Chief Technical Officer in May 2020. Sean joins Alvotech with a significant experience in biologics manufacturing (both mAb and AAV platforms), pharmaceutical (chemical) operations, technical operations strategy, QA compliance and research chemistry. Prior to joining Alvotech  Sean served as Site Head and Vice President of Manufacturing Operations at AveXis (a Novartis company) based in Illinois, USA. 

Sean played a leading role in the transformational change of AveXis’ core facility producing AAV9-based gene therapies to become a commercial supplier of live-saving medicines for patients with rare diseases. Prior to AveXis, Sean worked at Novartis headquarters in Basel, Switzerland, where he was the site head responsible for the manufacture of clinical biopharmaceutical drug substance (innovators and biosimilars) and the accelerated launch of three commercial products. After joining Novartis in 2009, Sean held roles of increasing responsibility in Technical Operations, including an assignment as strategic assistant to Novartis’ Global Head of Technical Operations, to develop, implement and monitor the company’s long-term technical operations strategy across more than 50 sites worldwide.

Sean holds a BSc with first class honours in chemistry, a PhD in organic chemistry from Loughborough University, UK, and a diploma in industrial studies. 

Sean Gaskell

Joel Morales became Chief Financial Officer at Alvotech in February 2020 after serving as CFO at sister company, Alvogen since 2017. Before joining Alvogen, he worked for Endo International plc, where he was SVP of the Generics Business Segment and Global Finance Operations. He was also responsible for a number of enterprise-wide strategic initiatives in direct support of the CEO and Executive Leadership Team. Prior to joining Endo, he worked for Merck & Co. and Schering-Plough, where he spent 10 years in various leadership roles, including the Corporate Strategy Office, Business Development and International Finance.

Joel began his career with KPMG LLP, and is a licensed certified public accountant in the State of New Jersey. He obtained his Bachelor of Science degree in accounting from Rutgers University.

Joel Morales

Andrew Roberts is Chief Portfolio Officer at Alvotech. He leads the portfolio strategy, including several enterprise leaderships functions responsible for the successful registration and partner commercialization of our biosimilars. 

Andrew comes to Alvotech with over 15 years of experience in both originator and biosimilar strategy and development.  Most recently, he led development portfolio strategy and several key collaborations for Sandoz's biosimilar portfolio. Prior to this Andrew led originator development teams in a variety of therapeutic areas within Novartis and has also worked on portfolio strategy at the group level for the Board of Directors. 

Andrew holds an Executive MBA from INSEAD and an MS in Nutrition and a BS in Biology from Louisiana State University.

Andrew Roberts

Anil comes to Alvotech with more than 15 years of professional working experience in the industry with an impressive track record as an expert negotiator in more than 1.000 (Deal Value: +$25bn) License, Acquisition, Supply, Distribution, Sales&Marketing Agreements and an excellent network. 

After completing his double-major degree with honors scholarship in Mathematics-Computer Engineering and Business Administration at Istanbul Kültür University and simultaneously at Vienna Technology University, he started his career as a Medical Representative in the Sanofi Group and then moved into the international markets division. He,  in the meantime,  he got an MBA at Galatasaray University. 

He then went on to hold different regional, functional and leadership roles in Abdi Ibrahim International Markets, including business development,  sales and marketing , region head along with a P&L responsibility of over € 100m, At Abdi Ibrahim, Anil created the market entry strategy for more than 30 new markets with successful execution.

Later, Anil moved to HELM AG based in Germany where he first held the role of Head of Sales and Licensing Department for Growth Markets and was later promoted to Global Head of Licensing and managed premier partnerships for small-molecules as well as Biosimilars through a joint venture with Gedeon Richter. Anil has general management experience with over 60 Headcounts spread in more than 20 countries worldwide.

Anil Okay

Reem Maliki is the Chief Quality Officer at Alvotech. Prior to joining Alvotech she held several roles at Mylan within the quality department, her latest being Head of Global Quality Operations, Affiliates and Third-Party and a member of the Senior Management Team. Prior to Mylan, Reem was Director of Quality Control and Director of Quality Investigations and CAPA at Andrx Pharmaceuticals, Inc. Earlier roles include a Technical Representative at Zymark Corporation and scientific roles at Wyeth-Ayerst Pharmaceuticals, Inc. 

Reem’s comprehensive experience extends over numerous product types, including biosimilars, injectables, oral solid dose, medical devices, and complex products. 

Reem holds a Bachelor of Science degree in Chemistry from the University of Maine.

Reem Malki

Rakel comes with a wealth of IT operational knowledge and an international track record that is a great asset to the company. Rakel joins us from the international orthopedics company Össur where she also worked as an CIO.

Prior to that, Rakel spent 14 years working at Arion Bank where, among other things, she headed the IT division as a CIO and was also a Managing Director of the marketing division.

Rakel has a B.Sc. in computer science from the University of Iceland (1997) and an MBA from Duke University (2002). 

Rakel Ottarsdottir

Before joining Alvotech Sigridur Elin was head of HR at the EFLA Consulting Engineering firm. Before that she worked at the University of Reykjavík for seven years as the head of the Human Resources and Quality division. She was then head of HR at deCODE genetics, a renowned world leader in human genetics, for 14 years and subsequently also became Operations Manager there.

Sigridur Elin has an MSc degree in international human resources management from the University of Leicester and a B.A. in sociology and industrial relations from the University of Iceland.

She also completed an Advanced Management Program at IESE in Barcelona and was a member of the board of directors of the Human Resources Association of Iceland for five years.

Sigridur Elin Gudlaugsdottir

Alvotech’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new biosimilar medicines quickly and safely to market. 

Robert Wessman is the founder and chairman of Alvotech as well as the CEO for global generic pharmaceuticals company Alvogen. The experienced leadership team is lead by Mark Levick, CEO.

World class team

Robert Wessman founded Alvotech in 2013 with the mission to set a new standard in biosimilars. Wessman’s initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland.